Research and Markets: Key Pharmaceutical Subsidiaries can be seen inside the Dainippon Pharmaceutical Company Intelligence Report.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c37571) has announced the addition of Dainippon Pharmaceutical Company Intelligence Report from Espicom Business Intelligence to their offering.

Pharmaceutical company intelligence reports provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Contents are as follows:-

--Executive Summary

--Product Portfolio/Research & Development

--Appendix 1 - Financial Performance

--Appendix 2 - Key Agreements

--Appendix 3 - Infrastructure

--Appendix 4 - Key Pharmaceutical Subsidiaries/Joint Ventures

--Appendix 5 - Product Index

--Index of Tables

--Index of Charts

Companies Mentioned Include:

--Almirall Prodesfarma SA

--Astellas Pharma

--AstraZeneca

--Conforma Therapeutics Corporation

--Eisai

--Gilead Sciences

--Idenix Pharmaceuticals Inc

--Kissei Pharmaceutical Co Ltd

--Kyorin Pharmaceutical Co Ltd

--Merck & Co

--Merck KGaA

--Merckle GmbH

--Mitsubishi Pharma Corporation

--Novartis

--Novo Nordisk

--Ono Pharmaceutical

--Protez Pharmaceuticals Inc

--Regeneron Pharmaceuticals Inc

--sanofi-aventis

--Schering-Plough

--Sunesis Pharmaceuticals Inc

--Taisho Pharmaceutical Co Ltd

For more information visit http://www.researchandmarkets.com/reports/c37571